Tumor-derived exosomes induce neutrophil infiltration and reprogramming to promote T-cell exhaustion in hepatocellular carcinoma

Wenchao Bi<sup>1</sup>, Xue Li<sup>2</sup>, Yu Jiang<sup>1</sup>, Tongtong Gao<sup>1</sup>, Huajun Zhao<sup>1</sup>, Qiuju Han<sup>1</sup>, Jian Zhang<sup>1</sup>

<sup>1</sup>Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, China.

<sup>2</sup>Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, China.

**Correspondence Author:** Qiuju Han, Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China. Email: <u>hanqiuju@sdu.edu.cn</u>; or Jian Zhang, Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China. Email: <u>zhangj65@sdu.edu.cn</u>.

#### **Supplement Information**

Supplementary Material and Methods Supplementary Tables 1-4 Supplementary Figures 1-12 Raw imaging

#### **Supplementary Material and Methods**

#### **Transmission electron microscopy**

Exosomes were suspended in 1×PBS and dropped on formvar-carbon-coated grids for 1 min. Absorb excess liquid by filter paper and wash with deionized water. Then, the exosomes were negatively stained with 1% phosphotungstic acid. After drying, the morphology of exosomes was characterized by a JEM-1011 transmission electron microscope (JEOL, Japan).

#### Nanoparticle size analysis

Exosomes were diluted with 1×PBS. The particle size distribution of exosomes was analyzed by Malvern Zetasizer Nano ZS-90 (Malvern, UK).

#### **Transwell assay**

Tranwell plate (Corning, 3415) was used to evaluate neutrophil migration. Briefly, neutrophils ( $1 \times 10^6$ ) treated with or without SB225002 were suspended in 100  $\mu$ L RPMI 1640 medium and added to the upper chamber. HCC exosomes suspended in 500  $\mu$ L RPMI 1640 medium or conditioned medium of indicated neutrophils were added to the lower chamber. After 12 h, cells in the lower chambers were counted to determine the migrated neutrophil number.

#### Cell apoptosis assay

Neutrophil apoptosis was analyzed by using an Annexin V/APC apoptosis detection kit (62700-80, Biogems) or Annexin V-FITC/PI apoptosis detection kit (40302, Yeasen) according to the manufacturer's instructions. For liver-infiltrating

neutrophils of mice, liver mononuclear cells were blocked with rat serum and then stained with anti-CD11b and anti-Ly6G fluorochrome-conjugated antibodies, followed by apoptosis detection. Data were collected using the BD FACSCelesta system.

#### **Co-culture of neutrophils and T cells**

The mouse spleen was passed through a 200-µm nylon cell strainer to obtain a single-cell suspension. Primary T cells were sorted using the EasySep<sup>TM</sup> Mouse T Cell Isolation Kit (19851, Stemcell). Splenic T cells ( $1 \times 10^6$ ) were cultured in a 12-well plate with RPMI 1640 medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. Anti-mouse CD3 $\epsilon$  antibody (1 µg/mL, 1100340, Biolegend) and anti-mouse CD28 antibody (4 µg/mL, 102116, Biolegend) were added. At the same time, mBMDNs ( $1 \times 10^6$ ) pre-treated with or without Hepa 1-6-exosomes were added. After 48 h, these cells were collected, and T cell function was analyzed by flow cytometry.

#### Hematoxylin-eosin staining

Hematoxylin-eosin staining experiment was completed with the assistance of Lilai Biotechnology Co., Ltd. (Chengdu, China). Briefly, liver tissues were fixed with 4% paraformaldehyde, followed by dehydration, transparency, and paraffinembedding. Paraffin sections were dewaxed to water and sequentially stained with hematoxylin and eosin. Dehydrate and transparent the slices again, and finally sealed with neutral gum. Images were captured using VS120 microscope (Olympus, Japan).

#### Immunofluorescence and confocal microscopy

To detect the uptake of exosomes by neutrophils, exosomes were stained with PKH26 (UR52302, Umibio) and added to neutrophils for 4 h. Then, the cells were fixed with 4% paraformaldehyde at 37 °C for 15 min and nuclei were stained with the Antifade Mounting Medium with DAPI (P0131, Beyotime). Images were acquired and analyzed under a Zeiss LSM 900 with Airyscan 2 software (Carl Zeiss, Germany).

#### **Bioinformatics analysis**

Infiltration of neutrophils in liver cancer or normal liver was determined by GEPIA2021 (gepia2021.cancer-pku.cn) analysis of TCGA and GTEx databases [1]. Infiltration of neutrophils in different stages of liver cancer was determined by the Assistant for Clinical Bioinformatics (www.aclbi.com) analysis of TCGA databases. Overall survival of liver cancer patients with high or low levels of neutrophil infiltration scores was determined by TIMER2.0 (timer.cistrome.org) analysis of TCGA databases [2]. Expression of miRNA in liver cancer and circulation was determined by CancerMIRNome (bioinfo.jialab-ucr.org/CancerMIRNome/) analysis of TCGA databases [3]. Expression of CYLD and NKRF in liver cancer or normal liver was determined by GEPIA2 (gepia2.cancer-pku.cn) analysis of TCGA databases [4]. Protein expression of CYLD and NKRF in liver cancer or normal liver was determined by UALCAN (ualcan.path.uab.edu) analysis of data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) [5]. The correlation of miR-362-5p expression and prognosis in liver cancer patients was determined by Kaplan-Meier Plotter (www.kmplot.com/analysis/) [6].

#### References

1. Li C, Tang Z, Zhang W, Ye Z, Liu F. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res. 2021; 49: W242-W6.

2. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48: W509-W14.

3. Li R, Qu H, Wang S, Chater JM, Wang X, Cui Y, et al. CancerMIRNome: an interactive analysis and visualization database for miRNome profiles of human cancer. Nucleic Acids Res. 2022; 50: D1139-D46.

4. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47: W556-W60.

5. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19: 649-58.

6. Győrffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation (Camb). 2024; 5: 100625.

5

### Supplementary Tables

Name	Supplier	Cat No.	Clone No.
Anti-CD9	Abcam	ab92726	EPR2949
Anti-β-actin	Abclonal	AC026	ARC5115-01
Anti-CYLD	Abclonal	A3821	N/A
Anti-GRP94	Abclonal	A0989	N/A
Anti-TSG101	Abclonal	A22166	N/A
Anti-GAPDH	Abways	AB0036	N/A
Anti-NF-kB p65	Affinity	AF5006	N/A
Anti-Phospho-NF-kB p65 (Ser536)	Affinity	AF2006	N/A
Anti-Alix	CST	92880S	E6P9B
Anti-CD81	CST	10037S	D5O2Q
Anti-Histone H3	CST	4499S	D1H2
Anti-CD81	Santa Cruz	sc-166029	B-11
Anti-CD9	Santa Cruz	sc-13118	C-4

 Table S1. Antibodies used in Western blotting and their technical information.

Fluorescein	Antibody	Species	Cat No.	Supplier
AF700	CD45.2	Mus musculus	109822	Biolegend
APC	PD-1	Mus musculus	135210	Biolegend
APC	IFN-γ	Mus musculus	17-7311-82	eBioscience
APC	CD11b	Homo sapiens	301310	Biolegend
APC/Cyanine7	CD14	Mus musculus	123318	Biolegend
APC/Cyanine7	NK1.1	Mus musculus	108724	Biolegend
BUV737	Ly6G	Mus musculus	367-9668-82	eBioscience
BV421	IFN-γ	Mus musculus	505830	Biolegend
BV510	Fixable Viability Dye	Mus musculus	65-0866-14	eBioscience
BV605	PD-L1	Mus musculus	124321	Biolegend
BV711	IFN-γ	Mus musculus	564336	BD Horizon
FITC	CD11b	Mus musculus	11-0112-85	eBioscience
FITC	CD15	Homo sapiens	11-0159-42	eBioscience
FITC	CD3	Mus musculus	100204	Biolegend
PE	CD11b	Mus musculus	12-0112-83	eBioscience
PE	TNF-α	Mus musculus	12-7321-82	eBioscience
PE	CD69	Mus musculus	12-0691-83	eBioscience
PE	CD8a	Mus musculus	12-0081-83	eBioscience
PE-CF594	CD8a	Mus musculus	100762	Biolegend
PE-Cy7	TIGIT	Mus musculus	142108	Biolegend
PE-Cy7	TNF-α	Mus musculus	25-7321-82	eBioscience
PerCP/Cyanine5.5	CD3	Mus musculus	100218	Biolegend
PerCP/Cyanine5.5	Ly6G	Mus musculus	127616	Biolegend
PerCP/Cyanine5.5	Tim3	Mus musculus	119718	Biolegend

**Table S2.** Antibodies used in flow cytometry and their technical information.

Gene	Species	Primer (5'-3')		
β-actin	Homo sapiens	Forward	CACCATTGGCAATGAGCGGTTC	
		Reverse	AGGTCTTTGCGGATGTCCACGT	
CXCL1	Homo sapiens	Forward	AGCTTGCCTCAATCCTGCATCC	
		Reverse	TCCTTCAGGAACAGCCACCAGT	
CXCL2	Homo sapiens	Forward	GGCAGAAAGCTTGTCTCAACCC	
		Reverse	CTCCTTCAGGAACAGCCACCAA	
CXCL8	Homo sapiens	Forward	GAGAGTGATTGAGAGTGGACCAC	
		Reverse	CACAACCCTCTGCACCCAGTTT	
<b>T</b> 10	Homo sapiens	Forward	CCACAGACCTTCCAGGAGAATG	
IL-IP		Reverse	GTGCAGTTCAGTGATCGTACAGG	
IL12b	Homo sapiens	Forward	GACATTCTGCGTTCAGGTCCAG	
		Reverse	CATTTTTGCGGCAGATGACCGTG	
	Homo sapiens	Forward	CTCTTCTGCCTGCTGCACTTTG	
Πηγ-α		Reverse	ATGGGCTACAGGCTTGTCACTC	
	Homo sapiens	Forward	TACCTGAACCCGTGTTGCTCTC	
төг-р		Reverse	GTTGCTGAGGTATCGCCAGGAA	
	Homo sapiens	Forward	GCCACTACTGTGCCTTTGAGTC	
MMP9		Reverse	CCCTCAGAGAATCGCCAGTACT	
D.,0	Homo sapiens	Forward	GCTGCCATCCACTGACTCGTAA	
BV8		Reverse	CTCCAGAGCGATTACTTTTGGGC	
CCL2	Homo sapiens	Forward	AGAATCACCAGCAGCAAGTGTCC	
		Reverse	TCCTGAACCCACTTCTGCTTGG	
p50	Homo sapiens	Forward	GCAGCACTACTTCTTGACCACC	
		Reverse	TCTGCTCCTGAGCATTGACGTC	
-50	Homo sapiens	Forward	GGCAGACCAGTGTCATTGAGCA	
p52		Reverse	CAGCAGAAAGCTCACCACACTC	
p65	Homo sapiens	Forward	TGAACCGAAACTCTGGCAGCTG	
		Reverse	CATCAGCTTGCGAAAAGGAGCC	
	Homo sapiens	Forward	GCTTTTGCTGTGATGGTGGACTC	
DIKUJ		Reverse	CTTGACGGATGAACTCCTGTCC	
	Homo sapiens	Forward	CGATGGCACTTTCCTGTGGAAG	
TRAFI		Reverse	TACAGCCGCAGGCACAACTTGT	

Table S3.	Primer	sequences	for	RT-qPCR.

β-actin	Mus musculus	Forward	CATTGCTGACAGGATGCAGAAGG	
		Reverse	TGCTGGAAGGTGGACAGTGAGG	
CXCL1	Mus musculus	Forward	TCCAGAGCTTGAAGGTGTTGCC	
		Reverse	AACCAAGGGAGCTTCAGGGTCA	
CXCL2	Mus musculus	Forward	CATCCAGAGCTTGAGTGTGACG	
		Reverse	GGCTTCAGGGTCAAGGCAAACT	
IL-1β	Mus musculus	Forward	TGGACCTTCCAGGATGAGGACA	
		Reverse	GTTCATCTCGGAGCCTGTAGTG	
II 10h	Mus musculus	Forward	TTGAACTGGCGTTGGAAGCACG	
1L120		Reverse	CCACCTGTGAGTTCTTCAAAGGC	
TNE	Mus musculus	Forward	GGTGCCTATGTCTCAGCCTCTT	
TNF-α		Reverse	GCCATAGAACTGATGAGAGGGAG	
	Mus musculus	Forward	TGATACGCCTGAGTGGCTGTCT	
ТӨГ-р		Reverse	CACAAGAGCAGTGAGCGCTGAA	
D	Mus musculus	Forward	TGCTGTGCTGTCAGTATCTGGG	
DVO		Reverse	TTCGCCCTTCTTCTTTCCTGCC	
CCL2	Mus musculus	Forward	GCTACAAGAGGATCACCAGCAG	
CCL2		Reverse	GTCTGGACCCATTCCTTCTTGG	
RNU6	Homo sapiens	Forward	CTCGCTTCGGCAGCACA	
	Mus musculus	Reverse	AACGCTTCACGAATTTGCGT	
miD 106h 5m	Homo sapiens	Forward	CCCTAGGTAGTTTCCTGTTGTTCG	
IIIIK-1700-5p	Mus musculus	rorward		
miR-205-5p	Homo sapiens	Forward	TCCTTCATTCCACCGGAGTCTG	
	Mus musculus			
miR-342-3p miR-21-5p	Homo sapiens	Forward	TCTCACACAGAAATCGCACCCG	
	Homo sanians			
	Mus musculus	Forward	GGCTAGCTTATCAGACTGATGTTGA	
miR-301a-3p	Homo sapiens		GGCAGTGCAATAGTATTGTCAAAGC	
	Mus musculus	Forward		
'D 262 5	Homo sapiens	<b>F</b> 1		
miR-362-5p	Mus musculus	Forward	CAAICUTTGGAACCTAGGTGTGAGT	

Plasmid	Primer (5'-3')		
WT-CYLD-1	Forward	CTAGCTAGCAAGTATGTTTGTGTTGGTTT	
	Reverse	CGGCTAGCCAACACCATTAAGGGAATTT	
WT-CYLD-2	Forward	CTAGCTAGCGAGACTAGGGTTTTAGACTG	
	Reverse	CGGCTAGCTCCCTCCATTTGTGGCCCTT	
Mut-CYLD-1	Forward	ATGGACGTTCCTAATGAAATCATTTTTCTTTTGTAGCTA	
	Reverse	TTTCATTAGGAACGTCCATAAAGAAGACACATTTATTTA	
Mut-CYLD-2	Forward	TGTGGCGTTCCTAAATGAAAAAGTGGGAAAGGAAGGTCC	
	Reverse	TTCATTTAGGAACGCCACACTTGCTGGTTAATGCATTAC	

 Table S4. Primer sequences for plasmid construction.

#### **Supplementary Figures 1-12**



Figure S1. HCC exosome induced CD4<sup>+</sup> T-cell exhaustion in the liver of HCC mice.

(A) The gating strategy for liver-infiltrating neutrophils. (**B**, **C**) The proportions of PD-L1<sup>+</sup> neutrophils and CD14<sup>+</sup> neutrophils in the liver were analyzed by flow cytometry. (**D**) The gating strategy for liver-infiltrating T cells. (**E-H**) Flow cytometry was performed to analyze the number of CD4<sup>+</sup> T cells (**E**) and CD8<sup>+</sup> T cells (**F**) in the liver, and the expression of PD-1, TIGIT, and TNF- $\alpha$  on liver-infiltrating CD4<sup>+</sup> T cells (**G**, **H**). Mock, healthy mice; DEN, DEN/CCl<sub>4</sub>-induced HCC mice; Exo, exosomes. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, and \*\*\*\**p* < 0.0001.



# Figure S2. Blocking the hepatic infiltration of neutrophils alleviates HCC exosome-induced T-cell exhaustion.

(A-F) Flow cytometry was performed to analyze the expression of PD-1, Tim3, IFN- $\gamma$ , and TNF- $\alpha$  on liver-infiltrating CD8<sup>+</sup> T cells (**A**, **D**) and CD4<sup>+</sup> T cells (**B**, **C**, **E**, and F) in mice. DEN, DEN/CCl<sub>4</sub>-induced HCC mice; Exo, exosomes;  $\alpha$ -Ly6g, anti-Ly6g blocking antibody. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \*p < 0.05, \*\*p < 0.01, and \*\*\*p < 0.001.



Figure S3. The identification of Huh-7 cell-exosomes and the purity of isolated neutrophils.

(A–C) Huh-7 cell-exosomes were isolated by ultracentrifugation and identified by transmission electron microscopy (A), particle size analyzer (B), and western blotting (C). (D, E) The purity of neutrophils isolated from human peripheral blood (D) or mouse bone marrow (E) was determined by flow cytometry. WCL, whole cell lysate; Exo, exosomes; mBMDNs, mouse bone marrow-derived neutrophils. One representative of at least three independent experiments.



Figure S4. HCC-exosomes induced migration, survival, and protumor polarization of mBMDNs *in vitro*.

(A) Heatmap of differentially expressed genes in neutrophils treated with or without Huh-7 cell-exosomes. (B) Hepa 1-6 cell-exosomes were added to recruit mBMDNs. After 12 h, the migration ability of mBMDNs was determined by the number of mBMDNs in the lower chamber. (C) RT–qPCR assay was performed to detect the expression of chemokines (CXCLs) in mBMDNs treated with or without Hepa 1-6 cell-exosomes. (D, E) NCM and NCM(Exo) were added to recruit mBMDNs treated with or without SB225002 (400nM). After 12 h, the migration ability of mBMDNs was determined by the number of mBMDNs in the lower chamber. (**F**) The apoptosis of mBMDNs treated with or without Hepa 1-6 cell-exosomes for 12 h was detected by Annexin V/7AAD staining. (**G**) GO enrichment analysis of differentially expressed genes related to N1-polarization pathways in human neutrophils treated with or without Huh-7 cell-exosomes. (**H**, **I**) RT–qPCR was performed to detect the expression of inflammation (**H**) and polarization (**I**) related genes in mBMDNs treated with or without Hepa 1-6 cell-exosomes. Exo, exosomes; NCM, conditioned medium from mBMDNs; NCM(Exo), conditioned medium from mBMDNs treated with Hepa 1-6 cell-exosomes. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, and \*\*\*\**p* < 0.0001.



Figure S5. HCC exosome-reprogrammed neutrophils induce CD4<sup>+</sup> T cell exhaustion.

(A) The purity of splenic T cells was determined by flow cytometry. (B) Splenic T cells isolated from healthy mice were co-cultured with mBMDNs treated with or without Hepa 1-6 cell-exosomes for 48 h. Flow cytometry was performed to analyze the expression of PD-1, CD69, IFN- $\gamma$ , and TNF- $\alpha$  on CD4<sup>+</sup> T cells. (C, D) Flow cytometry was performed to analyze the expression of PD-1, Tim3, IFN- $\gamma$ , and TNF- $\alpha$ 

on liver-infiltrating CD4<sup>+</sup> T cells. DEN, DEN/CCl<sub>4</sub>-induced HCC mice; Neu, mBMDNs; Neu(Exo), mBMDNs treated with Hepa 1-6 cell-exosomes; Exo, exosomes. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, and \*\*\*\*p < 0.0001.



Figure S6. HCC exosomes reprogram mBMDNs by activating the NF-κB signaling pathway.

(**A**, **B**) mBMDNs were treated with JSH-23 (400 nM), Hepa 1-6 cell-exosomes (40  $\mu$ g/mL), or the combination. Exosomes were added 2 h post JSH-23 treatment. The conditioned mediums from these mBMDNs were added to recruit mBMDNs (**A**). The apoptosis of mBMDNs was detected by Annexin V/7-AAD staining (**B**). (**C**) GSEA plot showing the enrichment scores for the TNF signaling pathway in human

neutrophils treated with Huh-7 cell-exosomes (40 µg/mL). (**D**, **E**) Human neutrophils were treated with Benpyrine (400 nM), Huh-7 cell-exosomes (40 µg/mL), or the combination. Exosomes were added 2 h post of Benpyrine treatment. The conditioned mediums from these neutrophils were added to recruit neutrophils (**D**). The apoptosis of neutrophils was detected by Annexin V/7-AAD staining (**E**). Exo, exosomes; NCM, conditioned medium from neutrophils; Ben, Benpyrine. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, and \*\*\*\**p* < 0.0001.



Figure S7. HCC exosomes induce miR-362-5p enrichment to promote chemotaxis and survival of mBMDNs.

(A) RT–qPCR assay was performed to detect the expression of miRNAs in mBMDNs treated with or without Hepa 1-6 cell-exosomes. (B) The levels of has-miR-301a-3p in liver cancer or normal liver were evaluated by using the CancerMIRNome database. (C) The levels of NKRF mRNA in liver cancer or normal liver were evaluated by using the GEPIA2 database. (D) The protein levels of NKRF in liver cancer or normal liver were evaluated by using the UALCAN database. (E, G) mBMDNs were transfected with NC or miR-362-5p inhibitor for 4 h and then treated with Hepa 1-6 cell-exosomes (40  $\mu$ g/mL) for another 12 h. The conditioned mediums as indicated

were collected to recruit mBMDNs (**E**). The apoptosis of mBMDNs was detected by Annexin V/7-AAD staining (**G**). (**F**, **H**) mBMDNs were transfected with NC or miR-362-5p mimic for 12 h. The conditioned mediums as indicated were collected to recruit mBMDNs treated with or without SB225002 (400nM) (**F**). The apoptosis of mBMDNs was detected by Annexin V-7-AAD staining (**H**). NC, negative control; inh, miR-362-5p inhibitor; Exo, exosomes; NCM, conditioned medium from neutrophils. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, and \*\*\*\**p* < 0.0001.



Figure S8. Blocking miR-362-5p promotes neutrophil infiltration and reverses T-cell exhaustion.

(A, B) Leukocytes were harvested from the spleen (A) or peripheral blood (B) of mice, and the percentage of neutrophils was determined by flow cytometry. (C) The expression of CXCR2 on neutrophils from the peripheral blood of mice was determined by using flow cytometry. (D, E) The expressions of PD-1, Tim3, and TNF- $\alpha$  on liver-infiltrating CD4<sup>+</sup> T cells (D) and CD8<sup>+</sup> T cells (E) of mice were determined by flow cytometry. (F, G) The expressions of IFN- $\gamma$  and TNF- $\alpha$  on splenic CD4<sup>+</sup> T cells (F) and CD8<sup>+</sup> T cells (G) of mice were determined by flow cytometry. Mock, healthy mice; DEN, DEN/CCl<sub>4</sub>-induced mice. Data are presented as mean  $\pm$ S.D. from at least three independent experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, and \*\*\*\*p < 0.0001.



### Figure S9. HCC exosome-reprogrammed neutrophils upregulate the expression of CXCL1, CXCL2, and CXCL8 in HCC cells.

(A) Huh-7 cells were treated with Huh-7 cell-exosomes. RT–qPCR assay was performed to detect the expression of chemokines (CXCLs) in Huh-7 cells. (B) Huh-7 cells were treated with conditioned medium from neutrophils and Huh-7 cell-exosome-reprogrammed neutrophils. RT–qPCR assay was performed to detect the expression of chemokines (CXCLs) in Huh-7 cells. Exo, exosomes; NCM, conditioned medium from human neutrophils; NCM(Exo), conditioned medium from human neutrophils treated with Huh-7 cell-exosomes. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \*p < 0.05 and \*\*p < 0.01.



# Figure S10. The mechanism of HCC exosome-induced immunosuppressive phenotype of neutrophils is unclear.

(A) mBMDNs were treated with JSH-23 (400 nM), Hepa 1-6 cell-exosomes (40  $\mu$ g/mL), or the combination. Exosomes were added 2 h post JSH-23 treatment. The expressions of PD-L1 and CD14 on neutrophils were determined by flow cytometry. (B) mBMDNs were treated with BBI608 (100 nM), Hepa 1-6 cell-exosomes (40  $\mu$ g/mL), or the combination. Exosomes were added 2 h post BBI608 treatment. The expressions of PD-L1 and CD14 on neutrophils were determined by flow cytometry.

(C) Human neutrophils treated with or without Huh-7 cell-exosomes or PMA (100 nM) for 12 h were stained with the SYTOX Green Nucleic Acid Stain to detect the formation of NETs. Exo, exosomes. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \**p* < 0.05 and \*\**p* < 0.01.



Figure S11. The expression of miR-362-5p in the circulation of cancer patients.

The expression of miR-362-5p in the circulation of cancer patients from the GSE106817 database.



Figure S12. HCC exosome-induced exhaustion of NK cells is not dependent on neutrophils.

(A-E) Flow cytometry was performed to analyze the proportion and number of NK cells in the liver (A), and the expression of PD-1, TIGIT, TNF- $\alpha$ , and IFN- $\gamma$  on liver-infiltrating NK cells (B-E). Mock, healthy mice; DEN, DEN/CCl<sub>4</sub>-induced HCC mice; Exo, exosomes;  $\alpha$ -Ly6g, anti-Ly6g blocking antibody. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, and \*\*\*\*p < 0.0001.

### Raw imaging







Figure 7D



#### Figure S4C



#### Figure 6M



